Author

James A. Shayman

Professor of Internal Medicine - Cited by 11,322

Biography

James A. Shayman is working as Professor  at University of Michigan Health System, USA. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect his wide range of publications in various national and international journals.
Title
Cited by
Year
Adipocyte ceramides regulate subcutaneous adipose browning, inflammation, and metabolism
B Chaurasia, VA Kaddai, GI Lancaster, DC Henstridge, S Sriram, ...Cell metabolism 24 (6), 820-834, 2016201
181
2016
Ceramides and glucosylceramides are independent antagonists of insulin signaling
JA Chavez, MM Siddique, ST Wang, J Ching, JA Shayman, SA SummersJournal of Biological Chemistry 289 (2), 723-734, 2014201
144
2014
1-O-acylceramides are natural components of human and mouse epidermis [S]
M Rabionet, A Bayerle, C Marsching, R Jennemann, HJ Gröne, Y Yildiz, ...Journal of lipid research 54 (12), 3312-3321, 2013201
88
2013
The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases
JA Shayman, SD LarsenJournal of lipid research 55 (7), 1215-1225, 2014201
45
2014
Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials
GM Brosnahan, KZ Abebe, CG Moore, FF Rahbari-Oskoui, KT Bae, ...American Journal of Kidney Diseases 71 (5), 666-676, 2018201
37
2018
Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury
TV Dupre, MA Doll, PP Shah, CN Sharp, D Siow, J Megyesi, J Shayman, ...Journal of Lipid Research 58 (7), 1439-1452, 2017201
36
2017
Lysosomal phospholipase A2
JA Shayman, JJG TesmerBiochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2019201
35
2019
Lysosomal phospholipase A2: A novel player in host immunity to Mycobacterium tuberculosis
BE Schneider, J Behrends, K Hagens, N Harmel, JA Shayman, ...European journal of immunology 44 (8), 2394-2404, 2014201
30
2014
A retractable lid in lecithin: cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein AI
KA Manthei, J Ahn, A Glukhova, W Yuan, C Larkin, TD Manett, L Chang, ...Journal of Biological Chemistry 292 (49), 20313-20327, 2017201
30
2017
Targeting glucosylceramide synthesis in the treatment of rare and common renal disease
JA ShaymanSeminars in nephrology 38 (2), 183-192, 2018201
30
2018
Glucosylceramide synthase inhibitors and therapeutic methods using the same
S Larsen, A Abe, L Shu, MW Wilson, RF Keep, JA ShaymanUS Patent 8,961,959, 2015201
30
2015
Lysosomal lipases PLRP2 and LPLA2 process mycobacterial multi-acylated lipids and generate T cell stimulatory antigens
M Gilleron, M Lepore, E Layre, D Cala-De Paepe, N Mebarek, ...Cell chemical biology 23 (9), 1147-1156, 2016201
28
2016
Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA. hy926 cells
N Kaissarian, J Kang, L Shu, MJ Ferraz, JM Aerts, JA ShaymanMolecular genetics and metabolism 125 (4), 338-344, 2018201
22
2018
Preferential hydrolysis of truncated oxidized glycerophospholipids by lysosomal phospholipase A2
A Abe, M Hiraoka, H Ohguro, JJ Tesmer, JA ShaymanJournal of Lipid Research 58 (2), 339-349, 2017201
21
2017
Targeting glycosphingolipid metabolism to treat kidney disease
JA ShaymanNephron 134 (1), 37-42, 2016201
18
2016
Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A
JJ Kang, L Shu, JL Park, JA Shayman, PF BodaryAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 306 (2 …, 2014201
17
2014
α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease
JJ Kang, NM Kaissarian, KC Desch, RJ Kelly, L Shu, PF Bodary, ...Kidney international 95 (1), 9-159, 2019201
14
2019
Eliglustat tartrate, a prototypic glucosylceramide synthase inhibitor
JA ShaymanExpert Review of Endocrinology & Metabolism 8 (6), 491-504, 202
13
2013
Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective
JA ShaymanAmerican Journal of Physiology-Renal Physiology 309 (), F996-F999, 2015201
12
2015
Inhibition of lysosomal phospholipase A2 predicts drug-induced phospholipidosis
V Hinkovska-Galcheva, T Treadwell, JM Shillingford, A Lee, A Abe, ...Journal of lipid research 62, 2021202
11
2021

Referred From: https://scholar.google.com/citations?user=wJWTs1gAAAAJ&hl=en

Cited by
Citations 11322
h-index 60
i10-index 158
Recommended Journals
Open Access Journals